Zhang Zhongying, Gu Xiang, Fang Xianghua, Tang Zhe, Guan Shaochen, Liu Hongjun, Wu Xiaoguang, Wang Chunxiu, Zhao Yan
Geriatric Department, Evidence-Based Medical Center, Xuanwu Hospital, Capital Medical University, Beijing, People's Republic of China.
Medical Affair Department, Beijing Friendship Hospital, Capital Medical University, Beijing, People's Republic of China.
Ther Clin Risk Manag. 2020 May 22;16:471-481. doi: 10.2147/TCRM.S239496. eCollection 2020.
The association between homocysteine and cardiovascular diseases (CVD) and all-cause death was inconclusive. A community-based prospective cohort study was carried out in Beijing to evaluate this association in elderly population for more effective clinical prediction and primary prevention of CVD.
Participants were randomly selected from Beijing, China. Questionnaire survey, physical examinations, and laboratory tests were carried out to collect baseline information and investigate clinical characteristics. Each participant was predetermined to be followed by 5 years. CVD events and death were collected as primary variables. A Cox regression analysis was performed to assess the risk of CVD events, CVD death, and all-cause death contributed by homocysteine as well as some other risk factors.
A total of 1257 participants with an average age of 69.16 years were enrolled in this study. After adjusting for confounders, the hazard ratios (HRs) and 95% confidence intervals of CVD event, CVD death, and all-cause death caused by intermediate-to-severe hyperhomocysteinemia as compared with normal homocysteine levels were 1.68 (95% CI 1.06-2.67), 1.97 (95% CI 0.95-4.29) and 2.02 (95% CI 1.26-3.24), respectively. Intermediate-to-severe hyperhomocysteinemia increased the risks of CVD event (HR 2.07, 95% CI 1.01-4.26) and all-cause death (HR 3.08, 95% CI 1.56-6.07) among male participants. However, the positive association was not statistically significant among female participants (HR 1.59, 95% CI 0.83-3.04 for CVD event and HR 0.90, 95% CI 0.52-6.07 for all-cause death). Every 5μmol/L increment in homocysteine concentration was shown to be associated with a 4% (HR 1.04, 95% CI 1.01-1.07) and 5% (HR 1.05, 95% CI 1.01-1.07) higher risk of CVD events and all-cause death in all participants. There was no significant association between moderate hyperhomocysteinemia and the risk of the CVD events and all-cause death.
Intermediate-to-severe hyperhomocysteinemia was significantly associated with CVD events and all-cause death in elderly population without a history of ischemia or congestive heart failure (CHF). The positive association was pronounced among males.
同型半胱氨酸与心血管疾病(CVD)及全因死亡之间的关联尚无定论。在北京开展了一项基于社区的前瞻性队列研究,以评估老年人群中的这种关联,从而更有效地对CVD进行临床预测和一级预防。
研究对象从中国北京随机选取。通过问卷调查、体格检查和实验室检测来收集基线信息并调查临床特征。每位参与者预定随访5年。收集CVD事件和死亡情况作为主要变量。进行Cox回归分析,以评估同型半胱氨酸以及其他一些风险因素导致CVD事件、CVD死亡和全因死亡的风险。
本研究共纳入1257名平均年龄为69.16岁的参与者。在对混杂因素进行校正后,与正常同型半胱氨酸水平相比,中度至重度高同型半胱氨酸血症导致CVD事件、CVD死亡和全因死亡的风险比(HR)及95%置信区间分别为1.68(95%CI 1.06 - 2.67)、1.97(95%CI 0.95 - 4.29)和2.02(95%CI 1.26 - 3.24)。在男性参与者中,中度至重度高同型半胱氨酸血症增加了CVD事件(HR 2.07,95%CI 1.01 - 4.26)和全因死亡(HR 3.08,95%CI 1.56 - 6.07)的风险。然而,在女性参与者中这种正相关无统计学意义(CVD事件的HR为1.59,95%CI 0.83 - 3.04;全因死亡的HR为0.90,95%CI 0.52 - 6.07)。在所有参与者中,同型半胱氨酸浓度每增加5μmol/L,CVD事件和全因死亡风险分别升高4%(HR 1.04,95%CI 1.01 - 1.07)和5%(HR 1.05,95%CI 1.01 - 1.07)。中度高同型半胱氨酸血症与CVD事件及全因死亡风险之间无显著关联。
在无缺血或充血性心力衰竭(CHF)病史的老年人群中,中度至重度高同型半胱氨酸血症与CVD事件和全因死亡显著相关。这种正相关在男性中更为明显。